Lymphangiogenic Gene Therapy With Minimal Blood Vascular Side Effects by Saaristo, Anne et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/09/719/12 $5.00
Volume 196, Number 6, September 16, 2002 719–730
http://www.jem.org/cgi/doi/10.1084/jem.20020587
 
719
 
Lymphangiogenic Gene Therapy With Minimal Blood 
Vascular Side Effects
 
Anne Saaristo,
 
1
 
 Tanja Veikkola,
 
1 
 
Tuomas Tammela,
 
1 
 
Berndt Enholm,
 
1
 
Marika J. Karkkainen,
 
1 
 
Katri Pajusola,
 
2 
 
Hansruedi Bueler,
 
2 
 
Seppo Ylä-Herttuala,
 
3
 
 
 
and Kari Alitalo
 
1
 
1
 
Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, the 
Haartman Institute and Helsinki University Central Hospital, University of Helsinki, 00014 Helsinki, Finland
 
2
 
Institute of Molecular Biology, University of Zurich, 8057 Zurich, Switzerland
 
3
 
A.I. Virtanen Institute and Department of Medicine, University of Kuopio, 70211 Kuopio, Finland
 
Abstract
 
Recent work from many laboratories has demonstrated that the vascular endothelial growth fac-
tor-C/VEGF-D/VEGFR-3 signaling pathway is crucial for lymphangiogenesis, and that muta-
 
tions of the 
 
Vegfr3
 
 gene are associated with hereditary lymphedema. Furthermore, VEGF-C
gene transfer to the skin of mice with lymphedema induced a regeneration of the cutaneous
lymphatic vessel network. However, as is the case with VEGF, high levels of VEGF-C cause
blood vessel growth and leakiness, resulting in tissue edema. To avoid these blood vascular side
effects of VEGF-C, we constructed a viral vector for a VEGFR-3–specific mutant form of
VEGF-C (VEGF-C156S) for lymphedema gene therapy. We demonstrate that VEGF-C156S
potently induces lymphangiogenesis in transgenic mouse embryos, and when applied via viral
gene transfer, in normal and lymphedema mice. Importantly, adenoviral VEGF-C156S lacked
the blood vascular side effects of VEGF and VEGF-C adenoviruses. In particular, in the lymph-
edema mice functional cutaneous lymphatic vessels of normal caliber and morphology were de-
tected after long-term expression of VEGF-C156S via an adeno associated virus. These results
have important implications for the development of gene therapy for human lymphedema.
Key words: lymphedema • lymphatic endothelium •  VEGF-C • VEGFR-2 • VEGFR-3
 
Introduction
 
Proangiogenic gene therapy, developed first in the pio-
neering work of Dr. Jeffrey Isner, has shown great promise
in the treatment of cardiovascular ischemic diseases (1–3).
In such studies, angiogenesis has been stimulated for exam-
ple by overexpression of vascular endothelial growth factor
 
(VEGF)
 
*
 
 or various fibroblast growth factors (FGFs). More
recent developments also include the use of modified forms
of the hypoxia-induced transcription factor (HIF)-1
 
 
 
,
which may orchestrate the induction of several angiogenic
mechanisms (4, 5). However, although VEGF is a potent
inducer of angiogenesis, the vessels it helps to create are
immature, tortuous, and leaky, often lacking perivascular
 
support structures (6–8). Only a fraction of the blood vessels
induced in response to VEGF in the dermis and in subcuta-
neous fat tissue were stabilized and functional after adeno-
 
viral treatment of the skin of nude mice (9, 10), while
intramuscular vessels developed into an angioma-like pro-
liferation or regressed with a resulting scar tissue (9, 11).
Furthermore, edema induced by VEGF overexpression
complicates VEGF-mediated neovascularization, although
recent evidence suggests that it can be avoided by provid-
ing angiopoietin-1 for vessel stabilization (12, 13).
Lymphatic vessels play an important physiological role in
homeostasis, regulation of tissue fluid balance, and in the
immune responses to pathogens, yet the molecular mecha-
nisms that control their development and function are only
beginning to be elucidated. So far, only two peptide
growth factors have been found capable of inducing the
growth of new lymphatic vessels in vivo. These factors,
VEGF-C and VEGF-D (14–16), belong to the larger
VEGF family of growth factors which also includes VEGF,
placenta growth factor (PlGF), and VEGF-B. VEGF-C and
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VEGF-D are ligands for the endothelial cell–specific tyro-
sine kinase receptors VEGFR-2 and VEGFR-3 (17, 18). In
adult human as well as mouse tissues VEGFR-3 is ex-
pressed predominantly in the lymphatic endothelial cells
which line the inner surface of lymphatic vessels (19, 20).
Whereas VEGFR-2 is thought to be the main mediator of
angiogenesis, VEGFR-3 signaling is crucial for the devel-
opment and maintenance of the lymphatic vessels (21). In-
hibition of VEGFR-3 signaling using soluble VEGFR-3
which competes for ligand binding with the endogenous
receptors led to lymphatic vessel regression in a transgenic
mouse model (22). Other molecules that have been re-
ported to be necessary for normal lymphatic development
include the transcription factor Prox-1 (23), the integrin 
 
 
 
9
(24), and angiopoietin-2 (25).
Impairment of lymphatic function, which results in in-
adequate transport of fluid, macromolecules, or cells from
the interstitium, is associated with a variety of diseases and
leads to tissue edema, impaired immunity and fibrosis (26).
Development of strategies for local and controlled induc-
tion of lymphangiogenesis would thus be of major impor-
tance for the treatment of such diseases. Adenoviral gene
transfer of VEGF-C in the skin has been shown to result in
a strong lymphangiogenic response (27, 28), but high lev-
els of VEGF-C also lead to blood vascular effects such as
increased vessel leakiness, presumably through the interac-
tion of VEGF-C with the VEGFR-2 expressed on blood
vascular endothelium (28). To develop a lymphatic-spe-
cific gene therapy approach without the unwanted blood
vascular side effects, we have studied the potential of a
VEGFR-3–specific mutant form of VEGF-C (VEGF-C156S)
as a therapeutic agent in lymphedema. We demonstrate
that stimulation of VEGFR-3 alone by VEGF-C156S po-
tently induces lymphangiogenesis both in transgenic em-
bryos and after virus-mediated gene transfer. In a lymph-
edema mouse model functional cutaneous lymphatic vessels
formed after intradermal infection with adeno-associated
virus (AAV) encoding VEGF-C156S. Most importantly,
VEGF-C156S essentially lacked the blood vascular effects
of native VEGF-C.
 
Materials and Methods
 
Generation and In Vitro Analysis of Recombinant Adenoviruses and
AAVs.
 
For the adenovirus construct, the full-length human
VEGF-C156S cDNA (29) was cloned as a BamHI/NotI frag-
ment into the corresponding sites of the pAD BglII vector. Rep-
lication-deficient E1-E3 deleted adenoviruses were produced in
293 cells and concentrated by ultracentrifugation (30). Adenoviral
preparations were analyzed to be free of helper viruses, li-
popolysaccharide, and bacteriological contaminants (31). The ad-
enoviruses encoding human VEGF-C and nuclear targeted 
 
LacZ
 
were constructed as described (27, 30). For the AAV construct,
the full-length human VEGF-C156S was cloned as a blunt-end
fragment into the MluI site of psub-CMV-WPRE plasmid and
the rAAV type 2 was produced as described previously (32).
AAVs encoding human VEGF-C and EGFP were used as con-
trols (32, 33).
 
For the analysis of protein expression, 293EBNA cells were in-
fected with recombinant adenoviruses for 2 h in serum-free me-
dium or by AAVs for 8 h in 2% FCS medium. After 24–72 h, the
cells were metabolically labeled for 8 h and subjected to immu-
noprecipitation with VEGF-C–specific antibodies or to a binding
assay using soluble VEGFR-2-Ig (R&D Systems) and VEGFR-
3-Ig (18) fusion proteins. AdLacZ and AAV-EGFP infected cells
were used as negative controls. The bound proteins were precip-
itated with protein G Sepharose, separated in 15% SDS-PAGE,
and analyzed by autoradiography. To compare the protein pro-
duction levels of AdVEGF-C156S and AdVEGF-C viruses, 20-
 
 
 
l aliquots of the media from AdVEGF-C156S, AdVEGF-C,
and AdLacZ infected cell cultures were separated in 15% SDS-
PAGE gel and subjected to Western blotting using polyclonal
anti–VEGF-C antibodies (R&D Systems).
 
In Vivo Use and Analysis of the Viral Vectors.
 
All the studies were
approved by the Committee for Animal Experiments of the
University of Helsinki. 5 
 
 
 
 10
 
8
 
 pfu of the recombinant adenovi-
ruses or 5 
 
 
 
 10
 
9
 
-1 
 
 
 
 10
 
11
 
 rAAV particles were injected intrader-
mally into the ears of NMRI nu/nu mice (Harlan) or Chy
lymphedema mice (32). The infected nude mice were killed 3, 5,
7, 10, 14, 21, 42, or 56 d after adenoviral infection and 3, 6, or 8
wk after AAV infection. The AAV-infected Chy mice were
killed 1, 2, 4, 6, or 8 mo after infection. Total RNA was ex-
tracted from the ears (RNAeasy Kit; QIAGEN) 1 to 8 wk after
adenoviral infection and 10 wk after AAV-infection. 10 
 
 
 
g of
RNA was subjected to Northern blotting and hybridization with
a mixture of [
 
 
 
32
 
P]dCTP (Amersham Biotech) labeled cDNAs
specific for VEGF-C. The glyceraldehyde-3-phosphate dehy-
drogenase cDNA probe was used as an internal control for equal
loading. The adenoviral protein expression was confirmed by
whole mount 
 
 
 
-galactosidase staining (34) of the AdLacZ-infected
ears 1 to 7 wk after gene transfer. The AAV-EGFP-infected ears
were studied under the fluorescence microscope at 3 wk to 8 mo
after infection.
 
 
 
-Galactosidase and Lectin Staining of Vessels.
 
For visualization
of the superficial lymphatic vessels in the K14-VEGF-C156S and
K14-VEGF-C embryos (15, 16), staged VEGFR-3
 
 
 
/LacZ em-
bryos were dissected, fixed in 0.2% glutaraldehyde, and stained
with X-gal (Sigma-Aldrich) for 
 
 
 
-galactosidase activity at
 
 
 
37
 
 
 
C. For the analysis of the adult cutaneous lymphatic pheno-
type, 
 
 
 
-galactosidase staining was performed for dissected adult
mouse ear skin.
In some of the adenovirus-infected mice, 
 
Lycopersicon esculen-
tum 
 
lectin staining was used to visualize the blood vessels in
whole mount (12). Biotinylated lectin (1 mg/ml; Vector Labora-
tories) was injected into the femoral veins of the mice under an-
esthesia and after 2 min the mice were killed and perfusion fixed
with 1% paraformaldehyde (PFA)/0.5% glutaraldehyde in PBS.
The tissues were dissected and the biotinylated lectin was visual-
ized by the ABC-DAB peroxidase method (Vectastain and
Sigma-Aldrich). Finally the tissues were dehydrated and mounted
on slides.
For the gene expression studies of different types of lymphatic
vessels, a combination of biotinylated lectin and whole mount
 
 
 
-galactosidase staining was performed for VEGFR-2
 
 
 
/LacZ
(35) and VEGFR-3
 
 
 
/LacZ (36) adult mouse tissues.
 
Analyses of the Lymphatic and Blood Vessels.
 
For immunohisto-
chemical analysis the mouse ears were dissected and fixed in 4%
PFA. Those ears that were analyzed in whole mount were incu-
bated in 5% H
 
2
 
O
 
2
 
 in methanol for 1 h to block endogenous per-
oxidase activity. The tissues were then blocked in 3% milk 0.3%
Triton-X in PBS overnight, and antibodies against the vascular 
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endothelial marker PECAM-1 (BD Biosciences) or VEGFR-3
(R&D Systems) were applied overnight at 
 
 
 
4
 
 
 
C. The visualiza-
tion was achieved with either the ABC-DAB peroxidase method
or with ABC-alkaline phosphatase using the alkaline phosphatase
substrate kit II (Vector Laboratories). Finally the tissues were flat-
tened and mounted on slides.
5-
 
 
 
m deparaffinized tissue sections were subjected to heat in-
duced epitope retrieval treatment or to an alternative enzyme
treatment. The endogenous peroxidase activity was blocked with
3% H
 
2
 
O
 
2
 
 in methanol for 20 min. Antibodies against VEGFR-3
(19), PECAM-1, podoplanin (a gift from Dr. Miguel Quintanilla,
Alberto Sols Biomedical Research Institute, Madrid, Spain), or
LYVE-1 (a gift from Dr. Erkki Ruoslahti, Burnham Institute, La
Jolla, CA) were applied overnight at 
 
 
 
4
 
 
 
C and staining was per-
formed using the tyramide signal amplification kit (NEN Life
Science Products) and 3-amino-9-ethyl carbazole (Sigma-
Aldrich). Hematoxylin was used for counterstaining.
To study the function of the cutaneous lymphatic vessels in the
Chy lymphedema mice, a small volume of FITC-labeled dextran
(MW 464 000; Sigma-Aldrich) was injected intradermally to the
periphery of mouse ear. Drainage of the dye via the lymphatic
vessels was followed under a fluorescence microscope.
 
Quantification of the Lymphangiogenic Response.
 
To quantify the
number of lymphatic vessels and branch points at 1 wk after ade-
noviral infection, six histological sections from ear midline with
the highest vessel density were chosen from each study group
(AdVEGF-C156S, AdVEGF-C, AdLacZ). The number of
LYVE-1–positive vessels and the number of branches in these
vessels were counted under a high power microscope. The area
analyzed in each sample was 4 mm
 
2
 
.
 
Permeability Assay.
 
The right ear of each mouse was infected
with AdVEGF-C156S, AdVEGF-C, or AdLacZ virus (5 
 
 
 
 10
 
8
 
pfu). The left ear received either AdLacZ (5 
 
 
 
 10
 
8
 
 pfu) or PBS
(in the AdLacZ group). 2 wk after the infection a modified Miles
permeability assay was performed as described previously (12). 1
 
 
 
l per gram of mouse weight of 3% Evans Blue was injected into
the femoral vein and after 2 min the mice were perfusion fixed
 
with 0.05 M citrate buffer (pH 3.5) in 1% PFA. The ears were
dissected, washed, weighed and extracted in formamide at
 
 
 
55
 
 
 
C overnight. The Evans Blue absorbance of the formamide
was then measured with a spectrophotometer set at 610 nm, and
the leakage (ng/mg) was compared between the right and left ear
of the same mouse.
 
Results
 
Expression of the Virally Transduced Genes In Vitro and In
Vivo.
 
The production of active VEGF-C156S and VEGF-C
proteins into the cell culture media of adenovirus (Ad)-
or AAV-infected, metabolically labeled 293EBNA cells
was confirmed by immunoprecipitation and by binding to
soluble VEGFR-2-Ig and VEGFR-3-Ig fusion proteins.
Both the partially processed 30 kD and the fully processed
21-kD forms of VEGF-C156S and VEGF-C bound to
VEGFR-3-Ig, but only the 21-kD form of VEGF-C was
capable of binding to VEGFR-2-Ig (Fig. 1 A, and unpub-
lished data). Furthermore, Western blotting analysis of me-
dia from the infected cultures confirmed that the same viral
titers of AdVEGF-C156S and AdVEGF-C gave rise to
comparable levels of the corresponding proteins in vitro
(Fig. 1 A). To analyze the expression of adenovirus and
AAV transduced genes in vivo, RNA samples from in-
fected mouse ear skin were analyzed by Northern blotting.
High levels of human VEGF-C156S and VEGF-C
mRNAs were detected in the AdVEGF-C156S and
AdVEGF-C infected tissues 1 wk after infection (Fig. 1 B).
3 wk after infection transgene expression in the control AdLacZ
infected ears was still strong (Fig. 1 C). Thereafter the trans-
gene expression was gradually down-regulated, and by 8
wk expression was no longer detected in the adenovirus-
infected ear. Somewhat weaker, but more sustained
Figure 1. Viral gene expression in
vitro and in vivo. (A) Comparison of
Ad-VEGF-C156S and AdVEGF-C re-
combinant protein production in vitro.
Top panels: the infected cells were meta-
bolically labeled and cell culture media
were subjected to precipitation with
VEGFR-3-Ig or VEGFR-2-Ig fusion
proteins. Medium from AdLacZ-infected
cells was used as a negative control. Bot-
tom panel: culture media of Ad-VEGF-C,
AdVEGF-C156S, and AdLacZ infected
cells were separated in 15% PAGE gel
followed by Western blotting using anti-
bodies against VEGF-C. (B) Viral trans-
gene expression in vivo. Northern blot
analysis of total RNA from mouse ears in-
fected with recombinant adenoviruses or
AAVs. The infecting virus and the dura-
tion of infection are indicated. (C)  -galac-
tosidase staining of the ear three weeks
after infection with AdLacZ. (D and E)
EGFP expression in the ear 6 wk and 8
mo after AAV-EGFP infection. 
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mRNA and protein expression was obtained with the AAV
vectors (Fig. 1, B and D). Furthermore, at 8 mo after infec-
tion, the latest time point studied, EGFP fluorescence was
still detected in the ear skin of the Chy mice infected with
the AAV-EGFP control virus (Fig. 1 E).
 
Comparison of the Lymphangiogenic Effects of VEGF-C156S
and VEGF-C in Transgenic Embryos.
 
To analyze the ef-
fects of VEGF-C156S and VEGF-C gene transfer in vivo,
the K14-VEGF-C156S and K14-VEGF-C transgenic
mice, which overexpress the factors in the basal cells of the
epidermis and have a severe hyperplasia of the dermal lym-
phatic vessels (15, 16), were crossed with the VEGFR-3
 
 
 
/
LacZ mice. In the latter mouse strain one allele of
VEGFR-3 has been replaced by the LacZ marker gene
by a knock-in strategy, allowing the visualization of the
VEGFR-3 expressing cells by 
 
 
 
-galactosidase staining. We
collected a series of staged K14-VEGF-C156S 
 
  
 
VEGFR-
3
 
 
 
/LacZ and K14-VEGF-C 
 
 
 
 VEGFR-3
 
 
 
/LacZ em-
bryos and analyzed the superficial lymphatic vessel pheno-
type after whole mount 
 
 
 
-galactosidase staining. Both
types of transgenic embryos developed normally up to em-
bryonic day 12.5 (E12.5). The first signs of lymphatic hy-
 
perplasia were detected in the transgenic embryos at E13.5
(unpublished data), consistent with the low level of activa-
tion of the K14-promoter at about E13 (37). At E14.5, the
cutaneous lymphatic vessels of both the K14-VEGF-C156S 
 
 
 
VEGFR-3
 
 
 
/LacZ and K14-VEGF-C 
 
 
 
 VEGFR-3
 
 
 
/
LacZ embryos were clearly hyperplastic (Fig. 2, A–C). In-
terestingly, whereas VEGF-C156S mainly induced enlarge-
ment of the preexisting lymphatic capillaries, VEGF-C
caused extensive lymphatic vessel sprouting (Fig. 2, D–F).
This effect was not due to a shift of VEGF-C signaling
from VEGFR-3 to VEGFR-2 in the VEGFR-3
 
 
 
/LacZ
heterozygous knock out embryos, as a similar phenotype
was observed with VEGFR-3 immunostaining in histolog-
ical sections of K14-VEGF-C156S and K14-VEGF-C
transgenic embryos (Fig. 2, G–I). Furthermore, in two in-
dependent K14-VEGF-C156S founder lines studied, the
higher VEGF-C156S dose resulted in an even more severe
hyperplasia but no increase in lymphatic sprouting.
To determine whether the differences in VEGF-C156S
and VEGF-C induced phenotypes were retained in adult
mice, whole mount 
 
 
 
-galactosidase staining of the adult skin
was performed. Also, in the adult transgenic mice a clear in-
Figure 2. Lymphangiogenesis
in the skin of K14-VEGF-
C156S and K14-VEGF-C trans-
genic embryos. (A–C) Superfi-
cial lymphatic vessels of
VEGFR-3 /LacZ heterozygous
E14.5 embryos visualized by
 -galactosidase staining. Note the
increase in the number of lym-
phatic capillaries in B and lym-
phatic capillary hyperplasia in A
(arrows). (D–F) Dorsal views of
the same embryos. (G–I) Cross
sections of the superficial lym-
phatic vessels of E14.5 K14-
VEGF-C156S and K14-VEGF-C
transgenic embryos stained with
antibodies against VEGFR-3.
(J–L) Cutaneous lymphatic ves-
sels of adult (age 8 wk)
VEGFR-3 /LacZ mice. The
lymphatic phenotype established
during embryonic development
is retained. Scale bars: A–C, 650
 m; D–F, 250  m; G–I, 35  m;
J–L, 150  m. 
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crease in the lymphatic vascularity of the skin was observed,
but again VEGF-C156S induced mainly lymphatic vessel
hyperplasia, whereas VEGF-C induced a strong increase in
the number of lymphatic vessels (Fig. 2, J–L).
 
Comparison of the Lymphangiogenic Potential of Recombinant
VEGF-C156S and VEGF-C Viruses.
 
We then wanted to
compare the lymphangiogenesis induced by viral delivery
of VEGF-C156S and VEGF-C. For this purpose, adenovi-
ruses encoding VEGF-C156S, VEGF-C, or LacZ were in-
jected intradermally into the ears of nu/nu mice. The first
sprouting lymphatic vessels were detected in the infected
ear skin by VEGFR-3 whole mount staining 3 to 4 d after
the adenoviral infection. The lymphatic sprouting was
more abundant in the AdVEGF-C–infected skin than in
the AdVEGF-C156S–infected skin at all time points stud-
ied. In the AdVEGF-C156S–infected skin the lymphatic
vessels enlarged progressively, and 1 wk after the infection
several lymphatic vessels appeared to be splitting to form
new daughter vessels (Fig. 3 A). At this time point nearly
all lymphatic vessels in the AdVEGF-C–infected skin ex-
hibited sprouting and bridging; some enlarged vessels were
also detected, whereas no signs of lymphangiogenesis were
seen in the AdLacZ-infected control skin (Fig. 3, B and C).
2 wk after AdVEGF-C156S infection the lymphatic vessels
network was vastly enlarged and most of the large vessels
had formed new sprouts or bridges (Fig. 3 D). At the same
time point the AdVEGF-C–infected skin was filled with
very actively sprouting, relatively small lymphatic vessels,
while only a few enlarged lymphatic vessels were detected
(Fig. 3 E). A few new lymphatic sprouts were detected in
only one AdLacZ-infected control mouse around the in-
jection wound (
 
n
 
 
 
  
 
15; unpublished data), otherwise the
lymphatic vasculature in the control skin remained unal-
tered (Fig. 3 F). The staining of histological sections for
VEGFR-3, LYVE-1, and podoplanin confirmed that the
sprouting of the lymphatic vessels was more efficient in the
AdVEGF-C than in the AdVEGF-C156S infected samples
(Fig. 3, G–I, and unpublished data). The newly formed
lymphatic vessels regressed gradually with time as expres-
sion of the viral genes was downregulated, and by 8 t to 10
wk after the infection the lymphatic vessel network had re-
turned to its normal architecture (unpublished data).
To quantify the lymphangiogenic response in the skin
after adenoviral infection, we counted in histological sec-
tions the number of LYVE-1–positive vessels and the num-
ber of branch points in these vessels. Both AdVEGF-C and
AdVEGF-C156S induced a significant increase in the
number of lymphatic vessels in comparison to the AdLacZ
controls (Fig. 4 A). Furthermore, the AdVEGF-C–infected
samples contained more LYVE-1–positive vessels than the
AdVEGF-C156S infected samples (P 
 
  
 
0.02), consistent
with the results obtained from the transgenic experiments.
The LYVE-1–positive vessels in the AdVEGF-C–infected
skin also had more branch points than the vessels in the
AdVEGF-C156S infected samples (P 
 
  
 
0.003; Fig. 4 B).
AAV vectors may be better suited for gene therapy than
adenoviral vectors due to the apparent lack of cell-medi-
ated immune response against AAV. We therefore tested
the ability of AAV-encoded VEGF-C156S to induce lym-
phangiogenesis in the mouse ear skin model. In VEGFR-3
whole mount staining of AAV-VEGF-C156S and AAV-
VEGF-C infected ear skin, sack-like enlargements in the
lymphatic vessels were detected 3 to 8 wk after the viral in-
fection (Fig. 5, A–F). In both cases most of these enlarged
Figure 3. Lymphangiogen-
esis in AdVEGF-C156S and
AdVEGF-C infected adult skin.
Whole mount VEGFR-3 staining
of the lymphatic vessels 1 wk (A–
C) and 2 wk (D–F) after infec-
tion. Note enlarged lymphatic
vessels (arrows) and sprouting or
splitting lymphatic vessels (arrow-
heads) in AdVEGF-C156S (A)
and AdVEGF-C (B) infected ears.
2 wk after infection, AdVEGF-
C156S infected ear (D) contains
large lymphatic vessels apparently
still undergoing sprouting and
splitting, whereas AdVEGF-C (E)
infected ear is filled with small
lymphatic sprouts. (G–I) Podo-
planin stained tissue sections at 2
wk after adenoviral infection.
Note the formation of a hyper-
plastic lymphatic network in
response to adenoviral VEGF-
C156S (G) and VEGF-C (H)
compared with AdLacZ control
(I). Sprouting and splitting of the
vessels is especially clear in the
AdVEGF-C infected ear (H).
Scale bars: A–C, 60  m; D–F,
220  m; G–I, 70  m. 
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vessels also exhibited new sprouts, but as in the adenoviral
experiments, the sprouting effect was more pronounced in
the AAV-VEGF-C–infected samples. This difference in
 
phenotype was also apparent in podoplanin-stained histo-
logical sections (Fig. 5, G and H). Overall, the lymphan-
giogenic response to both AAV-derived VEGF-C156S and
VEGF-C was weaker than that obtained with the adeno-
viral vectors.
 
Adenoviral VEGF-C156S Lacks the Blood Vascular Effects
of VEGF-C.
 
We have recently demonstrated that local
adenoviral VEGF-C expression induces blood vessel en-
largement, tortuosity, and leakiness (28). To see if a similar
blood vascular response results from adenoviral expression
of VEGF-C156S, we compared the dermal blood vessels in
the ear skin 1 to 2 wk after infection with AdVEGF-
C156S, AdVEGF-C, or AdLacZ. The vessels appeared
normal in AdVEGF-C156S and AdLacZ infected ears,
whereas in the AdVEGF-C–infected samples they were
tortuous and enlarged (Fig. 6, A–C). Also, in whole mount
PECAM-1 staining there were no obvious differences be-
tween the AdVEGF-C156S and AdLacZ infected samples
in the caliber or morphology of veins, arteries, or capillaries
(Fig. 6, D and F). However, the veins and venules of the
AdVEGF-C–infected samples were clearly dilated and tor-
tuous (Fig. 6 E).
To determine the effect of AdVEGF-C156S on blood
vessel permeability, AdVEGF-C156S, AdVEGF-C, or
AdLacZ viruses were injected into the right ears of nu/nu
mice, while AdLacZ infected left ears served as controls.
Extravasation of Evans Blue dye from ear blood vessels
was measured 2 wk after infection. There was no statisti-
cally significant difference in the blood vessel permeability
between the control ears and the AdVEGF-C156S–
infected ears (Fig. 7 A), whereas the leakage of Evans
Blue in the AdVEGF-C–treated ears was on an average 1.4
Figure 4. Quantification of the lymphangiogenic response in the adeno-
virus-infected samples. Number of LYVE-1 positive vessels in skin his-
tological sections (A) and number of branch points in these vessels (B)
were counted under a high power microscope.
Figure 5. Lymphangiogen-
esis in AAV-VEGF-C156S and
AAV-VEGF-C infected adult
skin. (A–F) Lymphatic vessels vi-
sualized with VEGFR-3 whole
mount staining 6 wk after in-
fection with the recombinant
AAVs. Note the enlargement,
sprouting (arrowheads), and
splitting (arrows) of the lym-
phatic vessels in response to
VEGF-C156S and VEGF-C.
Lymphatic sprouting is more ob-
vious in the AAV-VEGF-C in-
fected ear (B and E) than in the
AAV-VEGF-C156S infected ear
(A and D). (G–I) Podoplanin
staining of histological sections at
the same time point. Note the
hyperplastic lymphatic vessel
network within the subcutis and
muscle cell layers of the skin in
the AAV-VEGF-C156S (G) and
AAV-VEGF-C (H) infected
samples. Scale bars: A–C, 150
 m; D–F, 60  m; G–I, 70  m. 
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fold greater than in the AdLacZ-infected control ears
(Fig. 7 A).
The systemic effects of AdVEGF-C156S, AdVEGF-C,
and AdLacZ were studied by injecting 5 
 
 
 
 10
 
8 
 
or 1 
 
  109
pfu of the viruses into the tail veins of C57/Bl6 mice. All
mice that had received intravenous AdVEGF-C156S or
AdLacZ appeared healthy during the 2-wk follow-up pe-
riod, whereas all mice that had received different doses of
Figure 6. Adenoviral VEGF-
C156S does not affect blood
vessel morphology. (A–C) Ears
photographed 1 wk after adeno-
viral infection. Note the dilation
and tortuosity of blood vessels in
the AdVEGF-C infected skin (B)
compared with the AdVEGF-
C156S (A) and AdLacZ (C) in-
fected skin. (D–F) Whole mount
PECAM-1 staining of the ear
skin blood vessels at the same
time point. Compared with the
AdLacZ control (F), the veins
(V) and arteries (A) in the Ad-
VEGF-C156S infected skin (D)
appear morphologically normal,
whereas in the AdVEGF-C in-
fected ear (E) the veins are large
and tortuous. Note weak stain-
ing of lymphatic vessels (L) in F.
Scale bars: D–F, 150  m.
Figure 7. Adenoviral VEGF-C156S has a minimal effect
on vascular permeability. (A) The difference in permeabil-
ity between the treated versus the control ear measured by
Evans Blue concentration ratio (ng/mg). (B and C) Mouse
thoracic cavities photographed after systemic administra-
tion of AdVEGF-C156S or AdVEGF-C (1   109 pfu).
Note the accumulation of pleural fluid in the AdVEGF-C
infected mouse (C) but not in the AdVEGF-C156S in-
fected mouse (B).726 Lymphangiogenic Gene Therapy
AdVEGF-C became ill on day 3 after infection. Three of
the five mice that received the higher dose of AdVEGF-C
died during the first week. All mice infected with Ad-
VEGF-C had dose-dependent accumulation of fluid in
the thoracic cavity, but intrathoracic fluid was not ob-
served in any of the AdVEGF-C156S or AdLacZ infected
mice (Fig. 7, B and C). Two of the five mice that re-
ceived the higher dose of AdVEGF-C also had fluid in the
peritoneal cavity.
AAV-mediated VEGF-C156S Gene Transfer Results in
Formation of Functional Lymphatic Vessels in the Chy Lymph-
edema Mice. Similar to certain patients with Milroy’s dis-
ease, the Chy lymphedema mice have a germline inactivat-
ing mutation of VEGFR-3, which results in hypoplasia of
cutaneous lymphatic vessels (32). We have previously re-
ported that adenoviral or AAV-encoded VEGF-C is capa-
ble of restoring a functional cutaneous lymphatic vessel
network in the Chy mice (32). To assess the lymphangio-
genic activity of viral VEGF-C156S in the Chy mice, their
ears were injected with AAVs encoding VEGF-C156S,
VEGF-C, or EGFP. Fluorescent microlymphangiography
using FITC-dextran revealed that functional, normal-look-
ing, but slightly dilated lymphatic vessels had formed in the
AAV-VEGF-C156S infected mice during the 2-mo fol-
low-up period (Fig. 8, A–D); we also observed that in the
AAV-VEGF-C–infected Chy mice such vessels persisted at
least for 8 mo. As a rule, in Chy mice infected with AAV-
EGFP, FITC-dextran remained at the injection site, except
that a single draining lymphatic vessel was seen in 2/12 of
the mice (Fig. 8 C, and unpublished data). This finding
may reflect the occasional finding of isolated lymphatic ves-
sel segments in untreated Chy mice.
VEGFR-3 whole mount staining revealed only a few
large sack-like vessel structures in the AAV-EGFP–treated
Chy mice (Fig. 8 G). 5 wk after infection with AAV-
VEGF-C156S or AAV-VEGF-C, new VEGFR-3–positive
vessels were seen sprouting from these lymphatic remnants
(inset in Fig. 8 E). From 2 mo after VEGF-C156S or
VEGF-C gene transfer, branched lymphatic vessel network
was detected in the skin (Fig. 8, E and F). However, in
most cases the lymphatic vessels that formed in the skin of
the Chy mice in response to the lymphangiogenic gene
therapy appeared slightly hyperplastic in comparison with
those of wild-type mouse skin (Fig. 8, E–H).
VEGF-C Receptors Are Differentially Distributed in Lym-
phatic Vessels. The results with the VEGFR-3–specific
form of VEGF-C suggest that VEGFR-2 signaling is not
obligatory for lymphangiogenesis, although it has been re-
ported to be expressed in lymphatic endothelial cells in
vivo (28). To better understand these results, we compared
the lymphatic endothelial expression patterns of VEGFR-2
and VEGFR-3 in the respective heterozygous  -galactosi-
dase knock-in mice. In the skin of VEGFR-3 /LacZ
mice, the superficial lymphatic capillaries were strongly
stained, whereas in VEGFR-2 /LacZ mice, the lymphatic
staining was strongest in the collecting lymphatic vessels
(Fig. 9, A and B). To determine whether such distribution
patterns are specific to the skin, we analyzed other organs.
In the diaphragm of the VEGFR-3 /LacZ mice,  -galac-
tosidase staining was also found in the initial lymphatic cap-
illaries, whereas in the VEGFR-2 /LacZ mice the staining
was mostly seen in the collecting lymphatic vessels (Fig. 9,
C–F). However, in the mesenteric lymphatic vessels of the
small intestine the receptors were expressed at equally high
Figure 8. VEGF-C156S gene therapy in the Chy lymphedema mice. (A and B) AAV-mediated overexpression of VEGF-C156S (2 mo) and VEGF-C
(8 mo) induces the formation and maintenance of a functional lymphatic vessel network, as analyzed by fluorescent microlymphangiography. C and D
show comparison with noninfected Chy mouse ear and wild-type control ear, respectively. (E–H) VEGFR-3 whole mount staining of the ears 2 mo af-
ter AAV-infection. Note the formation of a tree-like network of lymphatic vessels in the skin of Chy mice in response to VEGF-C156S (E) and VEGF-C
(F). Inset in E shows lymphatic sprouting and splitting (arrowheads) in the AAV-VEGF-C156S infected Chy mouse skin 5 wk after infection. The con-
trol Chy mouse skin (G) contains few abnormal VEGFR-3–positive vessel structures. (H) VEGFR-3 staining of wild-type mouse skin. Scale bars: A–D,
250  m; E–H, 200  m.727 Saaristo et al.
levels (unpublished data). We have previously reported the
in the adult K14-VEGF-C mice the superficial cutaneous
lymphatic capillaries are hyperplastic (15), but the pheno-
type of the skin collecting lymphatic in these mice has not
been characterized. To study the collecting lymphatic ves-
sel phenotype in the K14-VEGF-C mice, we crossed them
with VEGFR-2 /LacZ mice. However, the collecting
lymphatic vessels were not affected by the overexpression
of VEGF-C in the basal keratinocytes (Fig. 8, G and H).
Discussion
Our study shows that overexpression of VEGF-C156S, a
VEGFR-3–specific mutant form of VEGF-C, potently in-
duces lymphangiogenesis both during embryonic develop-
ment and in adult skin. Recombinant VEGF-C156S vi-
ruses were capable of inducing growth of lymphatic vessels
and the formation of new lymphatic sprouts, although the
latter effect was seen only in adults and was less pro-
nounced than with VEGF-C. In addition, we show that
VEGF-C156S does not have obvious effects on blood ves-
sels in contrast to VEGF-C, which also binds VEGFR-2
expressed on the blood vascular endothelium. In the Chy
lymphedema mice AAV-mediated gene transfer of VEGF-
C156S induced the formation of a functional lymphatic
vessel network into the skin.
The whole mount images of ongoing embryonic and
adult lymphangiogenesis that we present here suggest that
the mechanisms of lymphangiogenesis may be very similar
to those of angiogenesis (38) in that lymphangiogenesis also
appears to proceed via vessel enlargement, sprouting and
splitting. Also, like the angiogenic blood vessels, the newly
formed lymphatic vessels seem to require a continuous
growth factor stimulation in order to be maintained. Al-
though VEGF-C156S and VEGF-C both induced an in-
crease of lymphatic vascularity, their lymphangiogenic
mechanisms seemed to differ. The difference between the
capacities of VEGF-C156S and VEGF-C to induce new
lymphatic sprouts was most obvious in the transgenic skin
model. This suggests that activation of VEGFR-2 is re-
quired for the induction of lymphatic sprouting during
embryonic development. Indeed, we have evidence that
VEGFR-2 is expressed in the embryonic lymph sac endo-
thelium (unpublished data). Although VEGFR-3 activation
via viral VEGF-C156S expression seems sufficient for the
induction of lymphatic sprouting in adult tissues, a more
effective sprouting response may require VEGFR-2 signal-
ing also in adult tissues. An interesting possibility is that sig-
naling via VEGFR-2 and VEGFR-3 receptor heterodimers
is needed for efficient formation of vessel sprouts. Gene ex-
pression studies in cultured lymphatic endothelial cells after
VEGF-C156S and VEGF-C stimulation should reveal at
least some of the mechanisms behind the differences in
such lymphangiogenic phenotypes observed in vivo. On
the other hand, it is also possible that VEGF-C can recruit
other effector cells and factors needed for sprouting in adult
tissues better than VEGF-C156S.
The biological significance of VEGF-C–induced blood
vessel dilation and increased permeability is unknown.
These effects may at least in part result from receptor-
mediated vasodilation as veins and venules in adult skin have
been shown to express VEGFR-2 (28). Several angiogenic
growth factors including VEGF and bFGF are known to be
potent stimulators of nitric oxide production, and in vivo
studies have documented endothelium-dependent hypo-
tension in response to treatment with these growth fac-
tors (39, 40). VEGF-C has also been reported to stimulate
the release of endothelial nitric oxide, which could con-
tribute to enhanced vascular permeability (41). The results
we obtained with systemic administration of AdVEGF-C
resemble those reported after systemic administration of
AdVEGF by Thurston and coworkers (13). Also, patients
with tissue ischemia developed edema after VEGF gene
Figure 9. Molecular markers of adult lymphatic vessels. (A and B) Vi-
sualization of cutaneous lymphatic vessels in VEGFR-3 /LacZ and
VEGFR-2 /LacZ mice. Blood vessels are stained brown for biotinylated
lectin while the blue staining marks the expression of the   galactosidase
gene. Note that whereas VEGFR-2 is found in the collecting lymphatic
vessels with valves (arrows), VEGFR-3 expression is strong in the initial
lymphatic capillaries (arrowheads). (C and D) Lymphatic vessels on the
membranous part and (E and F) on the muscular part of the diaphragm.
(G and H) The collecting lymphatic vessels of a K14-VEGF-C  
VEGFR-2 /LacZ mouse and a VEGFR-2 /LacZ littermate control.
Scale bars: A and B, 320  m; C and D, 250  m; E and F, 120  m; G and
H, 180  m.728 Lymphangiogenic Gene Therapy
transfer (42). In contrast, we have thus far observed mini-
mal blood vascular effects with VEGF-C156S.
The lymphangiogenesis in response to AAV-VEGF-
C156S and AAV-VEGF-C was always weaker and slower
than lymphangiogenesis obtained with the corresponding
adenoviral vectors. This finding probably relates to differ-
ences in the biological properties of these two viral vectors.
It has been demonstrated that after an intramuscular AAV
infection, the level of transgene expression increased gradu-
ally over 5 to 10 wk after an initial lag phase of 1 to 2 wk
(43). With adenovirus vectors, transgene expression has
been detected already 24 h after infection, but after reach-
ing its peak during the first week after infection, the ex-
pression is rapidly downregulated (10), probably due to
direct cytopathic effects of the virus resulting in the
elimination of the virally transduced cells. In the present
study adenoviral gene expression was extinguished by eight
weeks after infection of nude mice. The lower transgene
expression levels and slower kinetics of AAV-VEGF-
C156S and AAV-VEGF-C infection seemed to result in
more controlled lymphangiogenesis than the acute high-
level expression obtained by the use of adenoviral vectors.
AAV could therefore be more suited for lymphangiogenic
therapy in humans. Importantly, AAV-mediated transgene
expression seems very stable as demonstrated by persistent
fluorescence in the AAV-EGFP–infected samples. We have
followed the AAV-VEGF-C–infected Chy mice for up to
8 mo after infection and found that functional skin lym-
phatic vessels are still present at this time point. This proba-
bly reflects continuous transgene expression from the inte-
grated viral vector rather than actual stabilization of the
newly formed lymphatic vessels. At present it is unclear
whether a single infection with a recombinant AAV vector
will produce life-long transgene expression or whether
vector readministration would be required.
The first lymphangiogenic growth factors were discov-
ered some time ago, but the molecular control of the for-
mation of the patterned hierarchy of lymphatic vessels is
still largely unknown. Here we report for the first time that
the endothelial cells of lymphatic vessels of different cali-
bers express different growth factor receptors on their sur-
face. This probably reflects subtle differences in the func-
tion of the lymphatic endothelium of the various vessels
and their abilities to respond to different types of stimuli.
Interestingly, in the K14-VEGF-C mice only the superfi-
cial lymphatic capillaries were hyperplastic, whereas the
collecting, VEGFR-2–positive lymphatic vessels appeared
normal. Previous microlymphograpy studies have indicated
that the function of the superficial lymphatic capillaries in
the K14-VEGF-C mice may be partly compromised (15).
As both capillaries and collecting vessels are needed for the
lymphatic drainage function, more attention should be paid
to the development of strategies to specifically target the
different types of lymphatic vessels. This issue will be of
major importance when designing molecular therapies for
human lymphedema.
Angiogenic gene therapy has raised concerns regarding
the potential stimulation of dormant tumor growth due to
increased tumor angiogenesis in response to elevated sys-
temic VEGF levels. In addition, high local levels of VEGF
after viral gene transfer have been shown to result in the
formation of hemangioma-like vascular tumors in murine
skeletal muscle, heart, and skin (10, 11, 44). VEGF-C has
also been shown to increase tumor angiogenesis and the re-
cruitment of inflammatory cells (45, 46), but the increased
angiogenesis was reversed by inhibition of VEGFR-2 (45).
The safety of angiogenic gene therapy, in particular VEGF
gene transfer, would be improved by a brief duration and
low level of localized transgene expression. In a lymphatic
vascular specific gene therapy without blood vascular side
effects the safety margin would be wider. For patients with
lymphatic hypoplasia, dysfunction, and edema, VEGF-
C156S gene therapy would thus seem like an attractive
choice. However, as tumor-induced lymphangiogenesis
has been associated with enhanced metastasis to the lymph
nodes (47–52) the risk of enhanced growth and spread of
dormant metastases needs to be carefully evaluated.
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